共 122 条
Conserved herpesvirus protein kinases
被引:63
作者:
Gershburg, Edward
[1
,2
,3
,4
,5
]
Pagano, Joseph S.
[2
,3
,4
]
机构:
[1] So Illinois Univ, Sch Med, Dept Med Microbiol Immunol & Cell Biol, Springfield, IL 62702 USA
[2] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA
[3] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA
[4] Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA
[5] So Illinois Univ, Sch Med, SimmonsCopper Canc Inst, Springfield, IL 62794 USA
来源:
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
|
2008年
/
1784卷
/
01期
关键词:
herpesvirus;
protein kinase;
Serine/Threonine kinase;
protein kinase inhibitor;
antiviral compound;
D O I:
10.1016/j.bbapap.2007.08.009
中图分类号:
Q5 [生物化学];
Q7 [分子生物学];
学科分类号:
071010 ;
081704 ;
摘要:
Conserved herpesviral protein kinases (CHPKs) are a group of enzymes conserved throughout all subfamilies of Herpesviridae. Members of this group are serine/threonine protein kinases that are likely to play a conserved role in viral infection by interacting with common host cellular and viral factors; however, along with a conserved role, individual kinases may have unique functions in the context of viral infection in such a way that they are only partially replaceable even by close homologues. Recent studies demonstrated that CHPKs are crucial for viral infection and suggested their involvement in regulation of numerous processes at various infection steps (primary infection, nuclear egress, tegumentation), although the mechanisms of this regulation remain unknown. Notwithstanding, recent advances in discovery of new CHPK targets, and studies of CHPK knockout phenotypes have raised their attractiveness as targets for antiviral therapy. A number of compounds have been shown to inhibit the activity of human cytomegalovirus (HCMV)-encoded UL97 protein kinase and exhibit a pronounced antiviral effect, although the same compounds are inactive against Epstein-Barr virus (EBV)-encoded protein kinase BGLF4, illustrating the fact that low homology between the members of this group complicates development of compounds targeting the whole group, and suggesting that individualized, structure-based inhibitor design will be more effective. Determination of CHPK structures will greatly facilitate this task. (C) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:203 / 212
页数:10
相关论文